Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).
Cristina Cruz Zambrano
No relevant relationships to disclose
Martin H. Schuler
Consultant or Advisory Role - Novartis
Honoraria - Boehringer Ingelheim; Celgene; GlaxoSmithKline; Lilly; Novartis; Pfizer
Research Funding - Novartis
Jean-Pascal H. Machiels
Consultant or Advisory Role - Boehringer Ingelheim (U)
Research Funding - Novartis (B); Sanofi
Dagmar Hess
Stock Ownership - Novartis
Luis Paz-Ares
No relevant relationships to disclose
Ahmad Awada
No relevant relationships to disclose
Roger von Moos
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Roche
Honoraria - Bristol-Myers Squibb; Novartis; Roche
Research Funding - Roche
Neeltje Steeghs
No relevant relationships to disclose
Jordi Rodon Ahnert
No relevant relationships to disclose
Peggy De Mesmaeker
No relevant relationships to disclose
Heike Richly
No relevant relationships to disclose
Catherine Herremans
No relevant relationships to disclose
Markus Joerger
No relevant relationships to disclose
Jesus Corral Jaime
No relevant relationships to disclose
Maria Alsina
No relevant relationships to disclose
Fabienne Baffert
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
David Demanse
Employment or Leadership Position - Novartis
Vincent Duval
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Alex Morozov
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Luc Dirix
No relevant relationships to disclose